Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease

Frontiers in Pharmacology

Tengchuan Jin¹  Daniel Mekonnen²  Hylemariam Mihiretie Mengist³  Ahmed Mohammed⁵  Ronghua Shi⁵ 

[1] CAS Center for Excellence in Molecular Cell Science, Chinese Academy of Science, Shanghai, China;Department of Medical Laboratory Science, College of Health Science and Medicine, Bahir Dar University, Bahir Dar, Ethiopia;Department of Medical Laboratory Science, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia;Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China;Hefei National Laboratory for Physical Sciences at Microscale, Division of Life Sciences and Medicine, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, China;

关键词: potency;    safety;    pharmacokinetics;    inhibitors;    SARS-CoV-2;    main protease;   

DOI  :  10.3389/fphar.2020.630500

来源: DOAJ

【 摘 要 】

Effective, safe, and pharmacokinetically suitable drugs are urgently needed to curb the ongoing COVID-19 pandemic. The main protease or 3C-like protease (Mpro or 3CLpro) of SARS-CoV-2 is considered an important target to formulate potent drugs corresponding to its crucial role in virus replication and maturation in addition to its relatively conserved active site. Promising baseline data on the potency and safety of drugs targeting SARS-CoV-2 Mpro are currently available. However, preclinical and clinical data on the pharmacokinetic profiles of these drugs are very limited. This review discusses the potency, safety, and pharmacokinetic profiles of potential inhibitors of SARS-CoV-2 Mpro and forward directions on the development of future studies focusing on COVID-19 therapeutics.

【 授权许可】

Unknown